Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can COVID-19 rapid tests slip into HIV and TB clinics without disrupting care?

NCT ID NCT05498727

Diagnosis Sponsor: Elizabeth Glaser Pediatric AIDS Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are studying whether adding rapid antigen testing for SARS-CoV-2 to HIV, maternal and child health, and tuberculosis clinics in Cameroon and Kenya increases the number of people tested and diagnosed with COVID-19. The study compares clinic activity before and after the tests are integrated. It includes pregnant and breastfeeding women, children over 2 years old, and adults attending HIV or TB services. The goal is to find more COVID-19 cases and link people to treatment without disrupting routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rapid antigen testing for SARS-CoV-2 integrated into HIV, maternal and child health, and tuberculosis clinics
What this could lead to
If it works, this approach could help clinics in low-resource settings find more COVID-19 cases and link people to care without disrupting HIV, TB or maternal services.
What could go wrong
The study measures testing and detection rates, not whether patients ultimately fare better. Adding COVID-19 testing to busy clinics could strain staff and supplies, and results may not apply to other countries or health systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

527,184 people

The number who actually took part.

Started

May 2022

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population will include attendees at the MNCH, HIV and TB clinics at all of the CCA project sites in Cameroon and Kenya. SARS-CoV-2 screening and testing will be offered to all attendees per the eligibility criteria below.

Ages

2 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * MNCH services: all pregnant and breastfeeding women coming for antenatal care or post-natal care will be offered SARS-CoV-2 screening and testing; all children \> 2 years brought to the facility for routine immunization or under 5 years old clinics and their mother or caregivers will also be offered this service. * HIV services: all children (2-17 years) and adults (\>18 years) attending HIV services, including those coming for a clinical or laboratory visit, those coming to collect medications or for counseling/support groups, and those who are accompanying patients (such as caregivers of HIV infected child, etc.) will be offered SARS-CoV-2 screening and testing. * TB services: all children (2-17 years) and adults (\>18 years) attending TB services, including those coming for a clinical or laboratory visit, those coming to collect medications or for TB preventive therapy, and those who are accompanying patients (such as parent of a child, household contact, etc). Exclusion Criteria: * Clinic attendees from MNCH, HIV and TB clinics who tested positive for SARS-CoV-2 within the past two weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19

Contacts and locations

Locations

  • Health facilities in Cameroon

    Yaoundé, Cameroon

  • Health facilities in Kenya

    Nairobi, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.